Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 20Gastrointestinal 9Head & Neck 5Tumor-Agnostic 4Genitourinary 2Dermatologic 2CNS 2Breast 2Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Neoplasms 3Neoplasms, Unknown Primary 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 26Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Cyclophosphamide 12Radiosurgery 11Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Ipilimumab 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Erlotinib Hydrochloride × Tumor-Agnostic × 1 year × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
237 enrolled
Tumor-Agnostic

Neoplasms

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡